Syeda Hurmath

Nephrologist 👩‍⚕️|GlomCon fellow 2022-23 👩‍🎓. Travel enthusiast | Nature lover | Carpediem.

[Gopambuj Singh Rathod @IamGopambuj]

🧠 Post Renal Transplant Infections Timeline – Must Know!

🕒 0–1 month (Surgical phase)
• Nosocomial infections dominate
• UTI, SSI, pneumonia
• Not immunosuppression-driven

🕒 1–6 months (🔥 Peak immunosuppression)
• Opportunistic infections
• Cytomegalovirus infection (most common)
• Pneumocystis jirovecii pneumonia, TB, fungi
• BK virus nephropathy

🕒 >6 months (Community phase)
• CAP, UTI, influenza
• Late CMV, PCP (if no prophylaxis)
• Post-transplant lymphoproliferative disorder

💡 Pearls:
✔ Timeline = diagnosis shortcut
✔ CMV = key player
✔ Think TB in India
✔ TMP-SMX prophylaxis saves lives
#GSR #BuddingNephros #Transplant #Infection

[Syeda Hurmath @DrSyeda_hurmath]

@GovindDrsuk @DrAkshayaJ @ISNkidneycare Congratulations mam

[Syeda Hurmath @DrSyeda_hurmath]

@Anaghashreyas @arvindcanchi Thank you

[Syeda Hurmath @DrSyeda_hurmath]

My first WCN conference in beautiful Japan—an enriching experience. Grateful for the opportunity to present my abstract. Thank you @arvindcanchi sir and Dr. Vinod Dibbur sir for your constant support, opportunity and guidance.#WCN2026

[Syeda Hurmath @DrSyeda_hurmath]

@heritagemedical @arvindcanchi Thank you

[NephroMemes @MemesNephro]

Photo of me when I read “creatinine and kidney function better after dialysis yesterday”

[Syeda Hurmath @DrSyeda_hurmath]

@tbosex67 @arvindcanchi @isn_india @ISNeducation @ECNeph @Isncon25 Not tried sir

[Syeda Hurmath @DrSyeda_hurmath]

Thank you @arvindcanchi sir.I’m grateful for your support and the opportunity.

[Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi]

We presented a poster on Desidustat in #CKD anemia - A real world experience 👉 at #ISNCON25 today. Most of the work on this poster was done by @DrSyeda_hurmath!

[Syeda Hurmath @DrSyeda_hurmath]

Had a great time at the #Onconephrology meet with Chennai Kidney Associates in the presence of the phenomenal Dr. Rimda Wanchoo @renalmyeloma .Always a pleasure reuniting with my Chennai gang! Thank you for an amazing evening.

PC : @WordsofHemnath

[Syeda Hurmath @DrSyeda_hurmath]

Thank you, Dr. Shruthi Tapiawala mam this amazing course turned transplant immunology from a maze into a clear path. Your clarity, patience, and passion made every complex concept easy to understand. I’m grateful for all the effort you put into teaching. @AtdiMumbaiLab

[Syeda Hurmath @DrSyeda_hurmath]

Level up your cancer-kidney care skills! #Onconephrology

[Chennai Kidney Associates @ChennaiKidney]

📢Dear Senior Nephrologists, Colleagues & PGs,
Join us at the #Onconephrology CME to witness expert-led case discussions on all key topics

🗓️ Date: December 16, 2025
🕒 Time: 6:00 PM - 9:00 PM
📍 Venue: Taj Wellington Mews, Chennai

[ASN Publications @asnpublications]

What are the drivers of preventable hospitalizations in patients with kidney diseases? And how can clinicians best intervene? This review in #ASNCJASN evaluates the current state of the science: https://t.co/chNdZ2jJ4B

[CME INDIA @CMEINDIA1]

SGLT2i & UTI: Continue or Stop?

🧩 Key Question:
What happens when patients with T2DM on SGLT2 inhibitors develop a new-onset UTI?
Should therapy be continued or discontinued thereafter?

🔍 Key Finding (EHJ, 2025 | doi:10.1093/eurheartj/ehaf788)

In >61,000 T2DM patients on SGLT2i (2015–2022):
🔹 6.3% developed a new-onset UTI during follow-up.
🔹 Those with UTI had markedly higher risks of:
  🫀 CV composite events (HR 3.18; 95% CI 2.88–3.51)
  💧 Renal composite events (HR 2.51; 95% CI 2.32–2.72)

After UTI, 32% stopped SGLT2i.
 🚫 Discontinuation increased:
  🫀 CV risk → HR 1.35 (1.20–1.53)
  💧 Renal risk → HR 1.35 (1.21–1.51)
 💊 No significant reduction in recurrent UTI risk (HR 0.96).

💡 Take-Home Message

🌊 New-onset UTI is a marker of vulnerability — signalling higher cardio-renal risk.

❌ Stopping SGLT2 inhibitors post-UTI worsens CV and renal outcomes, without lowering reinfection risk.

✅ Best approach:
 – Treat UTI appropriately 🔬
 – Resume or continue SGLT2 inhibitor once infection resolves
 – Maintain long-term CV-renal protection 🌿

🩺 Clinical Insight

“UTI is a complication; discontinuation is a setback.”
Keep the molecule — protect the heart & kidney, not just the bladder. 💚

Source:
📘 European Heart Journal (2025): Wu M-Z et al., Urinary tract infection and continuation of sodium–glucose cotransporter-2 inhibitors in diabetic patients.
🔗
https://t.co/Zqy6uCbVCv

[Syeda Hurmath @DrSyeda_hurmath]

Grateful for the opportunity to present a unique and challenging post-kidney transplant case at ISOT, Jaipur.

A special thanks to my mentors @arvindcanchi and Dr Vinod Dibbur for their constant support and guidance.
#ISOT2025

[Syeda Hurmath @DrSyeda_hurmath]

Interesting take on Kidney donors !
#ISOT2025

[Syeda Hurmath @DrSyeda_hurmath]

Don't let age be a barrier to saving a life. This story is a beautiful reminder of the power of giving.

#OrganDonation #BeADonor #AgeIsJustANumber

[Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi]

@sgulati2002 @isn_india @IndiaSoTx Congratulations!
Here is our paper on desidustat, was alloted an oral podium presentation. We had to change it to a poster presentation since the first author @DrSyeda_hurmath was refused a SChengen Visa. #ERA25

[Syeda Hurmath @DrSyeda_hurmath]

#ERA2025
Thank U @arvindcanchi sir, Dr Sanjeev Hiremath sir and Dr Srushti Hiremath for this incredible opportunity.

[Syeda Hurmath @DrSyeda_hurmath]

Just wrapped up the ISN Primer Course in Glomerular Diseases at Nairobi-such a fun and enriching experience! Special thanks to @adrianliew8 for the competitive GN Jeopardy which was the highlight: high energy, brain-teasing, and full of learning gems. #ISN #Gloms #Nairobi2025

[Chennai Kidney Associates @ChennaiKidney]

💫New algorithm proposed for cancer screening, detecting underlying malignancies, & guiding treatment in glomerular diseases—paving the way for more integrated, early detection strategies.

🔗Link to Original article https://t.co/ELL7ijplyr

#Onconephrology #Nephtwitter
#CKA